CYP enzymes and sEH are highly expressed in the liver [69], inhibition of sEH is beneficial in liver pathologies of different origins (e. g., high fat diet-mediated NAFLD [54], and CCl4-induced hepatic fibrosis [53]). The gene discussed is EPHX2; the disease is metabolic dysfunction-associated steatotic liver disease.